Processing

Please wait...

Settings

Settings

1. WO1996002556 - OLIGONUCLEOTIDES WITH ANTI-MDR-1 GENE ACTIVITY

Publication Number WO/1996/002556
Publication Date 01.02.1996
International Application No. PCT/US1995/009011
International Filing Date 18.07.1995
Chapter 2 Demand Filed 06.02.1996
IPC
A61K 38/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
C12N 15/11 2006.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
CPC
A61K 38/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
C12N 15/1138
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
1138against receptors or cell surface proteins
C12N 2310/315
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
2310Structure or type of the nucleic acid
30Chemical structure
31of the backbone
315Phosphorothioates
C12N 2310/321
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
2310Structure or type of the nucleic acid
30Chemical structure
32of the sugar
3212'-O-R Modification
Applicants
  • HYBRIDON, INC. [US/US]; One Innovation Drive Worcester, MA 01605, US
Inventors
  • SMYTH, Adrienne, P.; US
Agents
  • KERNER, Ann-Louise ; Hale and Dorr 60 State Street Boston, MA 02109, US
Priority Data
08/276,56718.07.1994US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) OLIGONUCLEOTIDES WITH ANTI-MDR-1 GENE ACTIVITY
(FR) OLIGONUCLEOTIDE A ACTIVITE ANTI-GENE MDR-1
Abstract
(EN)
Disclosed are synthetic oligonucleotides having a nucleotide sequence complementary to at least a portion of the multi-drug resistant-1 gene, or transcripts thereof, which portion encodes a nucleoside binding site. Also disclosed is a pharmaceutical formulation containing such oligonucleotides, and methods of treating multidrug resistant cancer cells, of preventing the expression of P170 in a cell, and of preventing the induction of multidrug resistance in a cancer cell.
(FR)
L'invention concerne un oligonucléotide synthétique comprenant une séquence nucléotidique complémentaire d'au moins une partie du gène 1 résistant à des médicaments multiples, ou des produits de transcription de ce dernier, ladite partie codant un site de liaison nucléosidique. Elle porte également sur une formule pharmaceutique contenant lesdits oligonucléotides et sur des méthodes de traitement des cellules cancéreuses résistant à de multiples médicaments, de prévention de l'expression de P170 dans une cellule, et de prévention de l'induction de la résistance à des médicaments multiples dans une cellule cancéreuse.
Latest bibliographic data on file with the International Bureau